AP3283A - N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors - Google Patents

N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Info

Publication number
AP3283A
AP3283A AP2012006269A AP2012006269A AP3283A AP 3283 A AP3283 A AP 3283A AP 2012006269 A AP2012006269 A AP 2012006269A AP 2012006269 A AP2012006269 A AP 2012006269A AP 3283 A AP3283 A AP 3283A
Authority
AP
ARIPO
Prior art keywords
coa carboxylase
carboxylase inhibitors
pyrazolospiroketone
acetyl
pyrazolospiroketone acetyl
Prior art date
Application number
AP2012006269A
Other languages
English (en)
Other versions
AP2012006269A0 (en
Inventor
Scott William Bagley
David Andrew Griffith
Daniel Wei-Shung Kung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2012006269A0 publication Critical patent/AP2012006269A0/xx
Application granted granted Critical
Publication of AP3283A publication Critical patent/AP3283A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AP2012006269A 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors AP3283A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10
PCT/IB2010/054908 WO2011058474A1 (en) 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Publications (2)

Publication Number Publication Date
AP2012006269A0 AP2012006269A0 (en) 2012-06-30
AP3283A true AP3283A (en) 2015-05-31

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006269A AP3283A (en) 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Country Status (39)

Country Link
US (4) US8288405B2 (es)
EP (3) EP2499139B1 (es)
JP (1) JP5114610B1 (es)
KR (2) KR101478517B1 (es)
CN (1) CN102695708B (es)
AP (1) AP3283A (es)
AR (1) AR078944A1 (es)
AU (1) AU2010317501B2 (es)
BR (1) BR112012011072A2 (es)
CA (1) CA2778886C (es)
CL (1) CL2012000999A1 (es)
CO (1) CO6541569A2 (es)
CR (1) CR20120190A (es)
CU (1) CU24077B1 (es)
DK (1) DK2499139T3 (es)
DO (1) DOP2012000128A (es)
EA (1) EA020153B1 (es)
EC (1) ECSP12011880A (es)
ES (1) ES2444543T3 (es)
GE (1) GEP20146169B (es)
HK (1) HK1173724A1 (es)
HN (1) HN2012000973A (es)
HR (1) HRP20140025T1 (es)
IL (1) IL219373A (es)
MA (1) MA33734B1 (es)
MX (1) MX2012005429A (es)
NI (1) NI201200089A (es)
NZ (1) NZ599815A (es)
PE (1) PE20121469A1 (es)
PL (1) PL2499139T3 (es)
PT (1) PT2499139E (es)
RS (1) RS53156B (es)
SI (1) SI2499139T1 (es)
TN (1) TN2012000192A1 (es)
TW (1) TWI394756B (es)
UA (1) UA102336C2 (es)
UY (1) UY33020A (es)
WO (1) WO2011058474A1 (es)
ZA (1) ZA201204231B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
NZ597050A (en) 2009-06-29 2014-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
JP5114610B1 (ja) 2009-11-10 2013-01-09 ファイザー・インク Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
PL2621493T3 (pl) * 2010-09-30 2017-01-31 Pfizer Inc. N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA
SI2632925T1 (sl) * 2010-10-29 2015-07-31 Pfizer Inc. Inhibitorji N1/N2-laktam acetil-CoA karboksilaze
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CU24164B1 (es) * 2011-04-22 2016-03-31 Pfizer Inhibidores sustituidos de acetil-coa carboxilasa
BR122019020716B1 (pt) 2011-09-02 2021-02-17 Incyte Holdings Corporation heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9133166B2 (en) 2013-03-14 2015-09-15 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
SG11201600711PA (en) 2013-09-12 2016-03-30 Pfizer Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
US10150728B2 (en) 2013-10-17 2018-12-11 Shionogi & Co., Ltd. Alkylene derivatives
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EA201790502A1 (ru) 2014-09-16 2017-10-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистоновых диметилаз
CN107001330A (zh) * 2014-09-17 2017-08-01 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂
JP6539285B2 (ja) 2014-11-10 2019-07-03 国立大学法人横浜国立大学 酸素発生用アノード
MD3262046T2 (ro) 2015-02-27 2021-03-31 Incyte Corp Săruri de inhibitori ai PI3K și procedee pentru prepararea lor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
EP3644998B1 (en) 2017-06-30 2024-04-10 Quixgen, Inc. Novel spirolactone compounds
KR102395451B1 (ko) 2017-11-21 2022-05-09 화이자 인코포레이티드 4-(4-(1-이소프로필-7-옥소-1,4,6,7-테트라히드로스피로[인다졸-5,4'-피페리딘]-1'-카르보닐)-6-메톡시피리딘-2-일)벤조산의 결정질 2-아미노-2-(히드록시메틸)프로판-1,3-디올 염
WO2019178480A1 (en) * 2018-03-15 2019-09-19 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
CN115666558A (zh) 2020-05-21 2023-01-31 盐野义制药株式会社 脂肪性肝病的治疗用药物
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011809A1 (en) * 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
EP1911753A1 (en) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2008065508A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Spiroketone acetyl-coa carboxylase inhibitors
WO2008088689A1 (en) * 2007-01-12 2008-07-24 Merck & Co., Inc. Substituted spirochromanone derivatives as acc inhibitors
WO2008125945A2 (en) * 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
WO2009014455A1 (en) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Email response time expectation system
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009144554A1 (en) * 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
EP1383501B1 (en) 2001-02-28 2007-04-04 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
DE602006019304D1 (de) 2005-11-18 2011-02-10 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
US8735595B2 (en) 2006-02-15 2014-05-27 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
CA2724603A1 (en) * 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
AU2009271634A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
NZ591615A (en) * 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
JP5114610B1 (ja) 2009-11-10 2013-01-09 ファイザー・インク Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
JP2013510191A (ja) 2009-11-10 2013-03-21 ファイザー・インク Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
PL2621493T3 (pl) 2010-09-30 2017-01-31 Pfizer Inc. N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA
CU24164B1 (es) * 2011-04-22 2016-03-31 Pfizer Inhibidores sustituidos de acetil-coa carboxilasa

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011809A1 (en) * 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
EP1911753A1 (en) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2008065508A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Spiroketone acetyl-coa carboxylase inhibitors
WO2008088689A1 (en) * 2007-01-12 2008-07-24 Merck & Co., Inc. Substituted spirochromanone derivatives as acc inhibitors
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2008125945A2 (en) * 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
WO2009014455A1 (en) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Email response time expectation system
WO2009144554A1 (en) * 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors

Also Published As

Publication number Publication date
EA201290191A1 (ru) 2012-12-28
US20140288111A1 (en) 2014-09-25
KR101550557B1 (ko) 2015-09-04
EP2499139A1 (en) 2012-09-19
IL219373A (en) 2014-04-30
KR20140034919A (ko) 2014-03-20
KR101478517B1 (ko) 2015-01-02
JP5114610B1 (ja) 2013-01-09
BR112012011072A2 (pt) 2017-06-20
TN2012000192A1 (fr) 2013-12-12
CU24077B1 (es) 2015-03-30
CN102695708B (zh) 2014-10-15
AP2012006269A0 (en) 2012-06-30
US8288405B2 (en) 2012-10-16
EP2676958B1 (en) 2015-07-01
PT2499139E (pt) 2014-02-10
US9139587B2 (en) 2015-09-22
RS53156B (en) 2014-06-30
CO6541569A2 (es) 2012-10-16
HN2012000973A (es) 2015-03-02
US8507681B2 (en) 2013-08-13
CL2012000999A1 (es) 2012-07-20
WO2011058474A1 (en) 2011-05-19
NI201200089A (es) 2012-08-20
SI2499139T1 (sl) 2014-01-31
US8802690B2 (en) 2014-08-12
US20130296319A1 (en) 2013-11-07
UY33020A (es) 2011-06-30
CA2778886C (en) 2014-01-07
EA020153B1 (ru) 2014-09-30
EP2676958A1 (en) 2013-12-25
EP2947082A1 (en) 2015-11-25
DK2499139T3 (da) 2014-01-27
UA102336C2 (uk) 2013-06-25
CR20120190A (es) 2012-05-24
MA33734B1 (fr) 2012-11-01
CU20120071A7 (es) 2013-05-31
DOP2012000128A (es) 2012-08-31
AU2010317501B2 (en) 2013-06-06
NZ599815A (en) 2013-04-26
KR20120099460A (ko) 2012-09-10
AR078944A1 (es) 2011-12-14
TW201127838A (en) 2011-08-16
ES2444543T3 (es) 2014-02-25
IL219373A0 (en) 2012-06-28
MX2012005429A (es) 2012-06-19
ZA201204231B (en) 2013-02-27
US20130030181A1 (en) 2013-01-31
ECSP12011880A (es) 2012-07-31
GEP20146169B (en) 2014-09-25
HK1173724A1 (en) 2013-05-24
EP2499139B1 (en) 2013-12-11
PE20121469A1 (es) 2012-11-01
CN102695708A (zh) 2012-09-26
US20110111046A1 (en) 2011-05-12
PL2499139T3 (pl) 2014-04-30
HRP20140025T1 (hr) 2014-02-14
JP2013510192A (ja) 2013-03-21
WO2011058474A8 (en) 2012-04-26
AU2010317501A1 (en) 2012-05-17
CA2778886A1 (en) 2011-05-19
TWI394756B (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
AP3283A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
HK1209733A1 (en) N1/n2-lactam acetyl-coa carboxylase inhibitors n1/n2- a
PT2621493T (pt) Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
GB2474952B (en) Level
HK1179477A1 (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
AP2009004880A0 (en) Spiroketone acetyl-COA carboxylase inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
EP2558099A4 (en) Kinase Inhibitors
GB201009731D0 (en) Kinase inhibitors
EP2480076A4 (en) IMIDAZOTHIAZOLIC INHIBITORS OF KINASES
GB0914726D0 (en) Kinase inhibitors
EP2410051A4 (en) NEW ACETYL-COA-CARBOXYLASE
GB0903650D0 (en) Glyoalase inhibitors
GB0902661D0 (en) Inhibitors
GB0915927D0 (en) Novel inhibitors
GB201018597D0 (en) Inhibitors
GB201104990D0 (en) Screw-fix level